Clinical Trials Logo

Clinical Trial Summary

Radiation therapy is considered a standard treatment option for the management of localized prostate cancer. Among the 20-30% of patients who recur, there is no consensus on the optimal salvage therapy. Salvage options available for isolated local recurrence include; temporary or permanent implantation of radioactive seeds into the prostate, complete removal of the prostate gland, use of low temperatures to treat the disease (cryotherapy), and high frequency ultrasound to treat the disease. There are risks of complications associated with all these treatments, and there is presently no consensus as to which treatment is the best. The aim of this pilot study is to look at the feasibility and toxicities of whole gland salvage treatment of the prostate using temporary implantation of radioactive seeds into the prostate.


Clinical Trial Description

Radiation therapy is considered a standard treatment option for the management of localized prostate cancer. Among the 20-30% of patients who recur, there is no consensus on the optimal salvage therapy. Salvage options available for isolated local recurrence include; temporary or permanent implantation of radioactive seeds into the prostate, complete removal of the prostate gland, use of low temperatures to treat the disease (cryotherapy), and high frequency ultrasound to treat the disease. There are risks of complications associated with all these treatments, and there is presently no consensus as to which treatment is the best. The aim of this pilot study is to look at the feasibility and toxicities of whole gland salvage treatment of the prostate using temporary implantation of radioactive seeds into the prostate. Reports of the efficacy and toxicities of whole gland salvage HDR brachytherapy for local recurrence after external beam radiation therapy are limited to single-institution studies with small sample sizes. Given that our institution has the highest volume of prostate brachytherapy cases in Ontario and that we receive a significant number of referrals from other cancer centres for brachytherapy, this study will aim to add to the literature and help guide salvage therapy practice within our institution. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02560181
Study type Interventional
Source Sunnybrook Health Sciences Centre
Contact
Status Active, not recruiting
Phase N/A
Start date August 2014
Completion date August 30, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Recruiting NCT05848011 - A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer Phase 2
Active, not recruiting NCT02562131 - PET-MR-PSA Prostate Cancer Recidive Study
Completed NCT04134130 - The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer N/A
Recruiting NCT03507595 - Evaluation of the Metastasis and Recurrence of Prostate Cancer
Active, not recruiting NCT04983628 - Molecular Profiling in Prostate Cancer
Completed NCT03739684 - Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer Phase 3
Recruiting NCT04686188 - Exploring the Mechanisms and Dynamics of Clonal Evolution Leading to Recurrence in Prostate Cancer
Active, not recruiting NCT04114825 - Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer Phase 2
Recruiting NCT05646550 - Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer Phase 1
Not yet recruiting NCT04876755 - MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer Phase 2
Recruiting NCT01938339 - Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer N/A
Completed NCT01857037 - Post-radiation Prostate Cancer Local Recurrences: Detection With Histoscanning™ and MRI N/A
Active, not recruiting NCT03444844 - Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer Phase 1/Phase 2
Completed NCT04102553 - F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence Phase 3
Completed NCT03443609 - Study of 68Ga-HBED-PSMA PET/CT and Conventional Imaging in Occult Biological Relapse Prostate Cancer N/A
Recruiting NCT05036226 - COAST Therapy in Advanced Solid Tumors and Prostate Cancer Phase 1/Phase 2
Completed NCT04324983 - Identification of Predictive Biomarkers N/A
Completed NCT02176161 - Metformin Prostate Cancer Adjuvant Trial Phase 2
Active, not recruiting NCT04734184 - A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer Phase 3